S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

ALS Association Launches Campaign to Combat Insurance Denials

One in three patients with ALS faces insurance denials for essential medications and equipment, according to the ALS Association. To confront this, the nonprofit has introduced the 'We Are Undeniable' campaign, providing families with pro bono legal resources and a guided appeal tool to bypass systemic delays.

ALS Association Launches Campaign to Combat Insurance Denials
Photo: Bio & News

The initiative centers on the Undeniable Kit, a free resource designed to help patients challenge denials for treatments, power wheelchairs, and in-home care. The organization acted after its internal review found that nearly all of 19 major commercial insurers impose clinical hurdles for the gene-targeted drug Qalsody that were never required by the FDA. About one-third of these insurers classify the FDA-approved treatment as investigational, effectively blocking access for patients who have only a two-to-five-year life expectancy following diagnosis.

For families like the Gonzalez household in Utah, these administrative barriers translate into lost time that cannot be recovered. Although the association successfully overturned a denial for Kayla Gonzalez, the process underscored the exhaustion families face when navigating complex insurance systems. The campaign aims to shift the burden away from patients by advocating for a policy where physician-prescribed treatments receive automatic coverage once approved by federal regulators.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!